home / stock / ngenf / ngenf quote
Last: | $2.09 |
---|---|
Change Percent: | -1.94% |
Open: | $2.1 |
Close: | $2.09 |
High: | $2.1 |
Low: | $2.09 |
Volume: | 1,197 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.09 | $2.1 | $2.09 | $2.1 | $2.09 | 1,197 | 07-19-2024 |
$2.06 | $2.11 | $2.06 | $2.15 | $2.056 | 54,291 | 07-18-2024 |
$2.17 | $2.19 | $2.17 | $2.22 | $2.15 | 23,361 | 07-17-2024 |
$2.19 | $2.26 | $2.19 | $2.28 | $2.11 | 39,606 | 07-16-2024 |
$2.27 | $2.29 | $2.27 | $2.29 | $2.22 | 37,729 | 07-15-2024 |
$2.25 | $2.29 | $2.25 | $2.29 | $2.19 | 75,690 | 07-12-2024 |
$2.2065 | $2.08 | $2.2065 | $2.25 | $2.03 | 145,520 | 07-11-2024 |
$2.055 | $2.07 | $2.055 | $2.112 | $2.01 | 141,504 | 07-10-2024 |
$2.0715 | $2.15 | $2.0715 | $2.15 | $2.05 | 34,560 | 07-09-2024 |
$2.1673 | $2.38 | $2.1673 | $2.38 | $2.05 | 90,172 | 07-08-2024 |
$2.3585 | $2.32 | $2.3585 | $2.42 | $2.31 | 245,462 | 07-05-2024 |
$2.3 | $2.23 | $2.3 | $2.3 | $2.02 | 144,795 | 07-04-2024 |
$2.3 | $2.23 | $2.3 | $2.3 | $2.02 | 144,795 | 07-03-2024 |
$2.04 | $2.05 | $2.04 | $2.15 | $2.04 | 76,184 | 07-02-2024 |
$2.16 | $1.945 | $2.16 | $2.16 | $1.945 | 113,804 | 07-01-2024 |
$1.98 | $1.97 | $1.98 | $2.1 | $1.85 | 175,222 | 06-28-2024 |
$1.97 | $2.105 | $1.97 | $2.24 | $1.95 | 118,244 | 06-27-2024 |
$2.1 | $1.83 | $2.1 | $2.1 | $1.83 | 142,089 | 06-26-2024 |
$1.83 | $1.8 | $1.83 | $1.92 | $1.7535 | 74,215 | 06-25-2024 |
$1.8 | $1.67 | $1.8 | $1.81 | $1.67 | 38,591 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical ...